Glucox Biotech AB

Glucox Biotech AB activity focuses on developing pharmaceutical treatments, targeting specific sources of reactive oxygen that causes oxidative stress in diabetes with its complications.

The idea behind Glucox Biotech’s therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species and thus improve blood glycemic control and also decrease the critical risks and delay progression of complications in type 2 patients as well as cellular damage in stroke and heart infarction. Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase (NOX4).

Kategorier: Pharma

Gå till Glucox Biotech ABs hemsida